Immune, targeted therapy and related issues of relapsed/refractory multiple myeloma

doi:10.3760/cma.j.cn371439-20200622-00074

Abstract

Abstract:

The new immune and targeted therapy medicines of multiple myeloma and recurrence of refractory multiple myeloma mainly include immunomodulatory drugs, proteasome inhibitors, monoclonal antibody, immune monitoring point inhibitors, histone deacetylase and chimeric antigen receptor. Although the emergence of new drugs and the application of autologous hematopoietic stem cell transplantation have significantly improved the prognosis of patients, more effective treatment methods and treatment strategies are still required to deal with the adverse reactions and the condition of recurrence during treatment.

Key words: Multiple myeloma, Molecular targeted therapy, Immunotherapy

Sun Ruijie, Shan Ningning. Immune, targeted therapy and related issues of relapsed/refractory multiple myeloma[J]. Journal of International Oncology, 2021, 48(6): 381-384.

References 30

[1]	Schinke M, Ihorst G, Duyster J, et al. Risk of disease recurrence and survival in patients with multiple myeloma: a german study group analysis using a conditional survival approach with long-term follow-up of 815 patients[J]. Cancer, 2020,126(15):3504-3515. DOI: 10.1002/cancr.32978. doi: 10.1002/cncr.v126.15
[2]	Nakamura K, Smyth MJ, Martinet L. Cancer immunoediting and immune dysregulation in multiple myeloma[J]. Blood, 2020,136(24):2731-2740. DOI: 10.1182/blood.2020006540. doi: 10.1182/blood.2020006540
[3]	Szalat R, Munshi NC. Novel agents in multiple myeloma[J]. Cancer J, 2019,25(1):45-53. DOI: 10.1097/PPO.0000000000000355. doi: 10.1097/PPO.0000000000000355
[4]	Chim CS, Kumar SK, Orlowski RZ, et al. Correction: management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond[J]. Leukemia, 2019,33(4):1058-1059. DOI: 10.1038/s41375-019-0410-3. doi: 10.1038/s41375-019-0410-3 pmid: 30842604
[5]	Morgan GJ, Gregory WM, Davies FE, et al. The role of maintenance thalidomide therapy in multiple myeloma: MRC myeloma Ⅸ results and meta-analysis[J]. Blood, 2012,119(1):7-15. DOI: 10.1182/blood-2011-06-357038. doi: 10.1182/blood-2011-06-357038
[6]	Gormley NJ, Ko CW, Deisseroth A, et al. FDA drug approval: elotuzumab in combination with lenalidomide and dexamethasone for the treatment of relapsed or refractory multiple myeloma[J]. Clin Cancer Res, 2017,23(22):6759-6763. DOI: 10.1158/1078-0432.CCR-16-2870. doi: 10.1158/1078-0432.CCR-16-2870 pmid: 28249893
[7]	Dimopoulos MA, Palumbo A, Corradini P, et al. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma[J]. Blood, 2016,128(4):497-503. DOI: 10.1182/blood-2016-02-700872. doi: 10.1182/blood-2016-02-700872 pmid: 27226434
[8]	Goldschmidt H, Moreau P, Ludwig H, et al. Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study[J]. Leuk Lymphoma, 2018,59(6):1364-1374. DOI: 10.1080/10428194.2017.1376743. doi: 10.1080/10428194.2017.1376743
[9]	Moreau P, Masszi T, Grzasko N, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma[J]. N Engl J Med, 2016,374(17):1621-1634. DOI: 10.1056/1516282. doi: 10.1056/NEJMoa1516282
[10]	Allegra A, Alonci A, Gerace D, et al. New orally active proteasome inhibitors in multiple myeloma[J]. Leuk Res, 2014,38(1):1-9. DOI: 10.1016/j.leukres.2013.10.018. doi: 10.1016/j.leukres.2013.10.018
[11]	Badros A, Singh Z, Dhakal B, et al. Marizomib for central nervous system-multiple myeloma[J]. Br J Haematol, 2017,177(2):221-225. DOI: 10.1111/bjh.14498. doi: 10.1111/bjh.2017.177.issue-2
[12]	Spencer A, Harrison S, Zonder J, et al. A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results[J]. Br J Haematol, 2018,180(1):41-51. DOI: 10.1111/bjh.14987. doi: 10.1111/bjh.2018.180.issue-1
[13]	Zhu H, Wang T, Xin Z, et al. An oral second-generation proteasome inhibitor oprozomib significantly inhibits lung cancer in a p53 independent manner in vitro[J]. Acta Biochim Biophys Sin (Shanghai), 2019,51(10):1034-1040. DOI: 10.1093/abbs/gmz093. doi: 10.1093/abbs/gmz093
[14]	Hurchla MA, Garcia-Gomez A, Hornick MC, et al. The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects[J]. Leukemia, 2013,27(2):430-440. DOI: 10.1038/leu.2012.183. doi: 10.1038/leu.2012.183 pmid: 22763387
[15]	Usmani SZ, Weiss BM, Plesner T, et al. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma[J]. Blood, 2016,128(1):37-44. DOI: 10.1182/blood-2016-03-705210. doi: 10.1182/blood-2016-03-705210 pmid: 27216216
[16]	Usmani SZ, Nahi H, Plesner T, et al. Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials[J]. Lancet Haematol, 2020,7(6):e447-e455. DOI: 10.1016/S2352-3026(20)30081-8. doi: 10.1016/S2352-3026(20)30081-8
[17]	Dimopoulos MA, Lonial S, White D, et al. Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study[J]. Blood Cancer J, 2020,10(9):91. DOI: 10.1038/s41408-020-00357-4. doi: 10.1038/s41408-020-00357-4 pmid: 32887873
[18]	Zhang T, Wang S, Lin T, et al. Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma[J]. Oncotarget, 2017,8(20):34001-34017. DOI: 10.18632/oncotarget.16987. doi: 10.18632/oncotarget.v8i20
[19]	Jagannath S, Heffner LT Jr, Ailawadhi S, et al. Indatuximab ravtansine (bt062) monotherapy in patients with relapsed and/or refractory multiple myeloma[J]. Clin Lymphoma Myeloma Leuk, 2019,19(6):372-380. DOI: 10.1016/j.clml.2019.02.006. doi: S2152-2650(18)31566-0 pmid: 30930134
[20]	Martin T, Baz R, Benson DM, et al. A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma[J]. Blood, 2017,129(25):3294-3303. DOI: 10.1182/blood-2016-09-740787. doi: 10.1182/blood-2016-09-740787
[21]	Badros A, Hyjek E, Ma N, et al. Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma[J]. Blood, 2017,130(10):1189-1197. DOI: 10.1182/blood-2017-03-775122. doi: 10.1182/blood-2017-03-775122
[22]	Ma Y, Liu W, Zhang L, et al. Effects of histone deacetylase inhibitor panobinostat (lbh589) on bone marrow mononuclear cells of relapsed or refractory multiple myeloma patients and its mechanisms[J]. Med Sci Monit, 2017,23:5150-5157. DOI: 10.12659/msm.904232. doi: 10.12659/MSM.904232
[23]	Wahaib K, Beggs AE, Campbell H, et al. Panobinostat: a histone deacetylase inhibitor for the treatment of relapsed or refractory multiple myeloma[J]. Am J Health Syst Pharm, 2016,73(7):441-450. DOI: 10.2146/ajhp150487. doi: 10.2146/ajhp150487
[24]	Liu JD, Sun CY, Tang L, et al. Efficacy and safety of panobinostat in relapsed or/and refractory multiple myeloma: meta analyses of clinical trials and systematic review[J]. Sci Rep, 2016,6:27361. DOI: 10.1038/srep27361. doi: 10.1038/srep27361
[25]	Ali SA, Shi V, Maric I, et al. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma[J]. Blood, 2016,128(13):1688-1700. DOI: 10.1182/blood-2016-04-711903.
[26]	Baumeister SH, Murad J, Werner L, et al. Phase I trial of autologous CAR T cells targeting NKG2D ligands in patients with AMN/MDS and multiple myeloma[J]. Cancer Immunol Res, 2019,7(1):100-112. DOI: 10.1158/2326-6066.CIR-18-0307. doi: 10.1158/2326-6066.CIR-18-0307 pmid: 30396908
[27]	Cohen AD, Garfall AL, Stadtmauer EA, et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma[J]. J Clin Invest, 2019,129(6):2210-2221. DOI: 10.1172/JCI126397. doi: 10.1172/JCI126397
[28]	Tai YT, Anderson KC. Targeting B-cell maturation antigen in multiple myeloma[J]. Immunotherapy, 2015,7(11):1187-1199. DOI: 10.2217/imt.15.77. doi: 10.2217/imt.15.77
[29]	Kim JR, Mathew SO, Mathew PA. Blimp-1/PRDM1 regulates the transcription of human CS1 (SLAMF7) gene in NK and B cells[J]. Immunobiology, 2016,221(1):31-39. DOI: 10.1016/j.imbio.2015.08.005. doi: 10.1016/j.imbio.2015.08.005
[30]	Wong SW, Comenzo RL. CD38 monoclonal antibody therapies for multiple myeloma[J]. Clin Lymphoma Myeloma Leuk, 2015,15(11):635-645. DOI: 10.1016/j.clml.2015.07.642. doi: 10.1016/j.clml.2015.07.642